EA2201 Educational Materials

Rectum Cancer

EA2201

A Phase II Study of Neoadjuvant Nivolumab plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

Physician and Research Staff Educational Material

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

Physician Fact Sheet

Schema, eligibility criteria, and treatment details

Patient Educational Material

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material.

Study Summary for Patients

Study objectives, eligibility criteria, and a simplified schema in lay language to provide a more visual description of the trial to patients. All site staff are encouraged to share this as appropriate when explaining the trial to potential participants.

Recruitment/Awareness Promotional Material

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. Note: this content can be utilized for site-specific and community outreach (e.g., webpages, informational handouts, posters, etc.) to encourage potential participants to talk with their doctor, or to contact a site where the study is open for more information. The content may not be modified, and the entities who implement this plan (not including clinical staff) must refrain from direct engagement with patients, except to encourage them to speak with their doctor, or to direct them to the trial page on ECOG-ACRIN or Cancer.gov.

Patient-Directed Communications Plan

Patient-friendly language, images, and sample social media posts for use by participating sites and patient advocates to promote awareness of and recruitment to this trial

Clinical Trial Home Page

View EA2201 Record on ClinicalTrials.gov

Review Other Active Trials